You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advanced Nitric Oxide Release Bactericidal Urinary Catheters

    SBC: BIOCREDE INC.            Topic: 300

    DESCRIPTION provided by applicant In Phase I Biocrede developed a completely new urinary tract silicone Foley catheter with a andgt month shelf life made from a proprietary polymeric formulation to effectively reduce catheter associated urinary tract infections CAUTI via nitric oxide NO release for andgt weeks Key features of the new technology include catheters continuously d ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: 105

    DESCRIPTION provided by applicant Traumatic brain injuries TBI are an area of significant unmet need with no approved therapeutics and a national burden of $ billion annually Astrocyte Pharmaceuticals is developing a small molecule pharmaceutical agent that would be administered by intravenous injection by emergency responders or a medical professional within hours of injury to limit n ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Improving Outcomes for Mechanically Ventilated Patients with the Digital EZ Board

    SBC: VIDATAK, LLC            Topic: 600

    DESCRIPTION provided by applicant Effective communication between patients and healthcare professionals is essential to achieve positive clinical outcomes Patients who are unable to communicate effectively e g patients with limited English proficiency LEP those who are hearing impaired aphasic or have oral tracheal intubation experience extreme frustration panic anxiety sleeplessne ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. GPCR antagonists as anti-Ebola virus entry inhibitors

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as biosafety level agents Currently there is no effective vaccine or therapeutic treatment against f ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Phase IIB: Portable Device for Telecare Monitoring of Elderly People

    SBC: BIOSENSICS LLC            Topic: NIA

    DESCRIPTION provided by applicant We propose to further develop field test and commercialize a reliable and robust sensor technology that allows the objective assessment of daily physical activity risk of falling frailty and activity organization among older adults in he home and community This is a Phase IIB STTR application During Phases Iandamp II BioSensics LLC in collaboration wit ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as biosafety level agents Currently there is no effective vaccine or therapeutic treatment against f ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Lipoprotein synthesis inhibitors for multi-drug resistant Gram-negative therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The increasing prevalence of drug resistant bacterial infections highlights the critical medical need for new agents that are not susceptible to existing resistance mechanisms Few new agents are in development for Gram negative bacteria which take up small molecules sparingly and efflux most compounds that reach the periplasm A particularly problematic group ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. A Structural Brain MRI Dementia Forecast Tool

    SBC: CORTICOMETRICS LLC            Topic: NIA

    DESCRIPTION provided by applicant Alzheimerandapos s disease AD the most common type of dementia is a devastating disease with no available treatment or prevention The current lifetime risk for a year old individual is estimated to be around Given current projections over million individuals will be diagnosed with Alzheimerandapos s disease by As the development of the ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Improved Performance of Neonatal Vascular Access Catheters via 3D Magnetic Printing

    SBC: N2 Biomedical, LLC            Topic: NICHD

    DESCRIPTION provided by applicant Clinical treatment of infants in the neonatal intensive care unit NICU is particularly challenging due to their small anatomies medical instability and immature physiological processes Treatment is often complicated by the lack of therapeutic devices and instrumentation designed specifically to accommodate this unique patient population For instance curr ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Portable Multimode Persufflation/Perfusion System for Extended Hypothermic Kidney Preservation

    SBC: GINER INC            Topic: NIDDK

    DESCRIPTION provided by applicant Portable Multimode Persufflation Perfusion System for Extended Hypothermic Kidney Preservation In over patients in the US started treatment for end stage renal disease ESRD These patients spend on average $ annually on treatment including dialysis In The U S the current waiting list for organ transplantation holds over patient ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government